Pharsight

Drugs that contain Pasireotide Pamoate

1. Signifor Lar Kit patents expiration

Can you believe SIGNIFOR LAR KIT received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6225284 RECORDATI RARE Somatostatin peptides
Jun, 2016

(7 years ago)

US7473761 RECORDATI RARE Somatostatin analogues
Dec, 2026

(2 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8822637 RECORDATI RARE Somatostatin analogues
Aug, 2023

(9 months ago)

US7759308 RECORDATI RARE Microparticles comprising somatostatin analogues
Oct, 2026

(2 years from now)

US9351923 RECORDATI RARE Extended-release composition comprising a somatostatin derivative in microparticles
May, 2028

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-268) Jun 29, 2025
New Indication(I-785) Jun 29, 2021
Orphan Drug Exclusivity(ODE) Dec 15, 2021
New Chemical Entity Exclusivity(NCE) Dec 14, 2017
New Product(NP) Dec 15, 2017
Orphan Drug Exclusivity(ODE-81) Dec 15, 2021

NCE-1 date: 14 December, 2016

Market Authorisation Date: 29 June, 2018

Treatment: Method of treating acromegaly; Method of treating disorders with an etiology comprising or associated with excess gh-secretion

Dosage: FOR SUSPENSION;INTRAMUSCULAR

More Information on Dosage

SIGNIFOR LAR KIT family patents

Family Patents